The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on 12.05.2021.
M/s Bharat Biotech International Ltd., Hyderabad (BBIL) had proposed to carry out a Phase- II/III clinical trial of Covaxin in the age group of 2 to 18 years. The trial will be conducted in 525 healthy volunteers.
In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.
As rapid regulatory response, the proposal was deliberated in Subject Expert Committee (SEC) (COVID-19) on 11.05.2021. The Committee after detailed deliberation recommended for grant of permission to conduct proposed Phase II/III clinical trial to certain conditions.
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…
Heart disease remains one of the leading causes of death worldwide, and in India, cardiovascular…
Delhi is witnessing a sharp rise in flu cases, particularly Influenza B and H1N1 (commonly…
In early February 2025, a tragic incident occurred in Eluru, Andhra Pradesh, where a 61-year-old…
Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…
In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…